China · Delayed Price · Currency is CNY Cathay Biotech Statistics
Total Valuation
Cathay Biotech has a market cap or net worth of CNY 27.63 billion. The enterprise value is 22.87 billion.
| Market Cap | 27.63B |
| Enterprise Value | 22.87B |
Important Dates
The next estimated earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Jul 29, 2026 |
Share Statistics
Cathay Biotech has 720.66 million shares outstanding. The number of shares has increased by 15.90% in one year.
| Current Share Class | 720.66M |
| Shares Outstanding | 720.66M |
| Shares Change (YoY) | +15.90% |
| Shares Change (QoQ) | -1.03% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 14.47% |
| Float | 288.36M |
Valuation Ratios
The trailing PE ratio is 43.80 and the forward PE ratio is 31.62.
| PE Ratio | 43.80 |
| Forward PE | 31.62 |
| PS Ratio | 7.84 |
| PB Ratio | 1.28 |
| P/TBV Ratio | 1.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 33.88 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 36.60 |
| EV / Sales | 6.49 |
| EV / EBITDA | 23.53 |
| EV / EBIT | 34.54 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.25, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.25 |
| Quick Ratio | 4.35 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.73 |
| Debt / FCF | -5.81 |
| Interest Coverage | 172.01 |
Financial Efficiency
Return on equity (ROE) is 2.88% and return on invested capital (ROIC) is 4.35%.
| Return on Equity (ROE) | 2.88% |
| Return on Assets (ROA) | 1.71% |
| Return on Invested Capital (ROIC) | 4.35% |
| Return on Capital Employed (ROCE) | 2.96% |
| Weighted Average Cost of Capital (WACC) | 6.37% |
| Revenue Per Employee | 1.91M |
| Profits Per Employee | 338,820 |
| Employee Count | 1,844 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 1.85 |
Taxes
In the past 12 months, Cathay Biotech has paid 100.07 million in taxes.
| Income Tax | 100.07M |
| Effective Tax Rate | 14.00% |
Stock Price Statistics
The stock price has decreased by -24.51% in the last 52 weeks. The beta is 0.41, so Cathay Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | -24.51% |
| 50-Day Moving Average | 43.26 |
| 200-Day Moving Average | 47.95 |
| Relative Strength Index (RSI) | 36.04 |
| Average Volume (20 Days) | 4,665,234 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cathay Biotech had revenue of CNY 3.52 billion and earned 624.78 million in profits. Earnings per share was 0.88.
| Revenue | 3.52B |
| Gross Profit | 1.15B |
| Operating Income | 661.94M |
| Pretax Income | 715.05M |
| Net Income | 624.78M |
| EBITDA | 971.98M |
| EBIT | 661.94M |
| Earnings Per Share (EPS) | 0.88 |
Balance Sheet
The company has 9.30 billion in cash and 707.70 million in debt, with a net cash position of 8.59 billion or 11.92 per share.
| Cash & Cash Equivalents | 9.30B |
| Total Debt | 707.70M |
| Net Cash | 8.59B |
| Net Cash Per Share | 11.92 |
| Equity (Book Value) | 21.59B |
| Book Value Per Share | 24.91 |
| Working Capital | 9.68B |
Cash Flow
In the last 12 months, operating cash flow was 815.41 million and capital expenditures -937.27 million, giving a free cash flow of -121.86 million.
| Operating Cash Flow | 815.41M |
| Capital Expenditures | -937.27M |
| Depreciation & Amortization | 310.04M |
| Net Borrowing | 149.32M |
| Free Cash Flow | -121.86M |
| FCF Per Share | -0.17 |
Margins
Gross margin is 32.56%, with operating and profit margins of 18.78% and 17.73%.
| Gross Margin | 32.56% |
| Operating Margin | 18.78% |
| Pretax Margin | 20.29% |
| Profit Margin | 17.73% |
| EBITDA Margin | 27.58% |
| EBIT Margin | 18.78% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.45, which amounts to a dividend yield of 1.17%.
| Dividend Per Share | 0.45 |
| Dividend Yield | 1.17% |
| Dividend Growth (YoY) | 12.50% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 48.72% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -15.90% |
| Shareholder Yield | -14.73% |
| Earnings Yield | 2.26% |
| FCF Yield | -0.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 20, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jul 20, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Cathay Biotech has an Altman Z-Score of 7.99 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.99 |
| Piotroski F-Score | 6 |